Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They charge 6.95 a trade
schwab charges a fee for RDGL in my wife’s IRA
I used to be Ameritrade, that became Swchab... I pay 6.95 commission. Go figure
me neither on schwab
I pay no commission fee at Fidelity
Etrade and Schwab, yes
Reminds me of the time, many years ago before Korenko was CEO, when the stock was sold at less than the par value. Like a ton of it and the price crashed hard (cause the price was already low given it was below the par value). Then someone said 'oops' thats not legal and I'm not sure how but the sale was rolled back and outstanding shares decreased a lot. Anyone who had bought shares at the lower price on the open market kept them and so they made out like bandits. I had bought some, but not as many as I had considered buying. I still made nice change (yes, I sold those few million shares once it rocketed back up).
Anyone around from those days that can explain that event? I always thought it was strange how it worked out and didn't understand what had happened. I also remember being really annoyed how the price started kicking up very hard a few days before the news hit that the roll back was going to happen. There were definitely folks who had information that the rest of us didn't have.
Strange trading early on. Bunch of trades at small volumes.. I havent seen that here before. Now I see a 26 sh trade. Cost more in commissions... MMs trying to do something?
On the Outstanding Shares reduction? Well if it isn't a typo on OTC Markets site then it's a pretty big deal.....just saying. There's clearly a discrepancy from a few weeks ago and the latest update.....
https://www.otcmarkets.com/stock/RDGL/security
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174728624
Everyone is locked and loaded, low volume and super thin.
Most Drs care but they are ruled from higher up and if they speak up they get licenses removed. Totally understand where you are coming from after the last 20 years especially the last 5 years....I'm not a fan at all of the medical industry. My grandparents taught and lived mostly natural treatments to the family. My daughter is a pediatrician. My one cousin was head of the respiratory therapy department in a fairly large hospital he recognized what was killing the patients he brought it to the attention of higher ups and they shut him down So he resigned and retired. My uncle and cousins were killed by the recent pan treatments in the hospital. Yes it was the treatments science has verified. So I totally understand.
Main reason for being here is to support an outpatient cancer treatment that I know works with minimal damage to the health of patients. And obviously to make a solid investment.
GLTA
TRUTHsocial
""Yes Dr's care""
Do you really think that statement is TRUE?????????????????
CANCER is a MULTI BILLION DOLLAR a year industry, DO YOU really think there are not already cures or at least treatments that stop the growth.
SORRY but when ya have this kind of money and CASH FLOW at stake, you don't really try to hard to kill the CASH COW.........................
I know this sounds very JADED but after what I have seen for some 72 years, I HAVE BECOME THAT WAY on a lot of issues
Does anyone care ???
Yes animals care
Yes people care
Yes investors care
Yes Dr's care
Yes cancer cares
That's who cares ....
Announcement coming soon imo about IDE FDA APPROVAL
2 weeks or less imo
Just a suggestion to anyone looking at the link King shared (also on Vivos X boards). Don't bother reading the article, just play the newscast video. At first I just read it (not wanting to bother with viewing the video) and was not impressed, but seeing the vet and how excited he was about having the product available gave me an entirely different impression.
https://www.21alivenews.com/2024/07/12/breakthrough-cancer-technology-saving-animals-lives-fort-wayne/
I think this response hints that once Radiogel is approved for human use maintream news may think it is a good story to cover. Until then I think they have a legitimate question of 'will anyone care'. But once its available for human use in anyone form (meaning even as an IDE for just thyroid cancer) anyone seeing and learning about the product could become a potential patient, thus making it more news worthy to cover.
Awesome news clip King! Vivos goal is regional clinics with at least one in every state. 2 or 3 per state depending on size/population of state.
With the increase in clinics and likely market approval for human use about this time in 2025, about 12 month or so, the ROI potential with $RDGL keep growing!!
Simple because you can’t have a previous estimate comment in the same comment of the original estimate. Therefore my question was what previous estimates, implying that there were previous posts made about estimates. It’s whatever, don’t have anymore time waste on answering your comments that contain unnecessary digs. This board has gone to crap over the years with all the roaches.
HONEY BADGER
Not sure what you got so PO'd about, he told ya in his post what his previous guesses about the price were............
Awesome video! Thank goodness the vet was there to talk about the product more than Korenko. Bless Korenko's little science heart, but he is not good on camera or much of a communicator. The vet was obviously very enthusiastic about the product and seemed very proud to have found the tech and brought it to his hospital early. Getting vets to talk up the product like this will get more vets clamoring for it!!
New Isopet News Clip Below
https://www.21alivenews.com/2024/07/12/breakthrough-cancer-technology-saving-animals-lives-fort-wayne/
Please pin
Then there's this.....????? https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174728624
familyof5
Re: CatfishHunter post# 176927
Thursday, July 11, 2024 11:46:21 PM
Any explanation why the Outstanding Shares where 417,610,992 on 07/01/24 and as of today’s update on OTC markets only 417,041,295?
That’s 569,697 less Shares showing in the Outstanding from 9 days ago????
https://www.otcmarkets.com/stock/RDGL/security
Any explanation why the Outstanding Shares where 417,610,992 on 07/01/24 and as of today’s update on OTC markets only 417,041,295?
That’s 569,697 less Shares showing in the Outstanding from 9 days ago????
https://www.otcmarkets.com/stock/RDGL/security
I like both of PPS up or down. If up, we are making money; if down, add more shares to make more money in the near future. Tomorrow we could have chance to buy more shares at cheapo, if stupid person sold at bid.
Rum, I'm new but love the big picture, not the day to day. I'm looking forward to the next few milestones. Dollars not cents!!!!
Well said. The last two minutes before the close was most certainly by no means a representation of how well the PPS performed today. Very Green Day for the most part even though we got that 60,000 share bid whack minutes before the close. Not a big deal to anyone long the stock.....
Rather presumptuous of you to make such a statement since you have no clue whatsoever why persons would choose to sell at this point.
The fact is that you're not in their shoes and as such your statement is one made out of ignorance.
Don't see any reason for the pointless hullabaloo over the pps swings since its obviously due to the low volume while we're all awaiting IDE news....in short, it wholly irrelevant!
In OTC, this is about as close as you can get to a sure thing. And people put thousands into far riskier lotto plays like $GTVH etc. go figure.
IDE isn’t a guarantee, goodluck…
Not sure they're idiots. Just a group lying to themselves they are powerful via selling on low volume. We'll be finding out pretty soon how significant said power is under tremendous volume post IDE approval. Rats roam every where when the cat is away.
It just scans whatever people say on these message boards as share price predictions. Nobody has a Chrystal ball not even ai
Or, someone who has millions of shares needed cash.
Either way, once IDE is approved, we should see a new 1 year (and should also be a 3 year) high, and a new bottom would set in above current levels.
Couple market sales right at the end of day. About 120K shares. Someone needing some cash and moving on. Small potatoes. Missing out on much bigger gains when IDE approval hits.
I have decided to stop getting worked up when price drops. Yes, it is frustrating, but I believe we will get approval from FDA. If/when that happens, share price should go boom.
Here is Google Gemini’s take on the likelihood of IDE acceptance and the impact to stock price:
5x to 10x returns!! I’ll take it.
Vivos, Inc. (RDGL) and the Potential Impact of an FDA IDE
Likelihood of Obtaining FDA IDE
Vivos, Inc. has already submitted an application for an Investigational Device Exemption (IDE) for its RadioGel™ product. The company has also received Breakthrough Device Designation from the FDA, which often expedites the development and review process.
Factors influencing the likelihood of obtaining an IDE:
Strength of preclinical data: The quality and robustness of the data supporting the safety and efficacy of RadioGel will significantly impact the FDA's decision.
Clarity and completeness of the IDE application: A well-organized and detailed application that addresses all FDA requirements will increase the chances of approval.
FDA's resource allocation and workload: The FDA's current workload and priorities may influence the review timeline.
While there's no guarantee of FDA approval, the factors mentioned above suggest a reasonable likelihood of Vivos obtaining an IDE.
Potential Stock Price Impact
If Vivos successfully obtains an FDA IDE, it would be a significant milestone for the company, as it would allow them to initiate human clinical trials. This could potentially lead to a substantial increase in the stock price.
Factors affecting the potential price increase:
Market perception of the IDE: Investor sentiment towards the IDE approval and its implications for the company's future prospects.
Overall market conditions: General market trends and investor appetite for biotech stocks.
Competitive landscape: The presence of other companies developing similar technologies could impact the valuation.
Potential price increase:
Given the speculative nature of the biotech industry and the early-stage development of RadioGel, a significant price increase (e.g., 5x-10x) is possible if the market reacts positively to the IDE approval. However, it's essential to consider that such a dramatic increase would be highly volatile and dependent on numerous factors.
A more conservative estimate might be a 2-3x increase in the stock price if the IDE approval is accompanied by positive clinical trial data and a clear development pathway.
Important Considerations:
The biotech sector is known for its volatility, and stock prices can fluctuate significantly based on news, clinical trial results, and overall market sentiment.
It's crucial to conduct thorough due diligence and consider the risks involved before investing in early-stage biotech companies.
What idiot sold at the end of the day? I hope they miss out on the explosion to come.
2 weeks until D day for rdgl
No feel free to if you like. I’m a spur of the moment poster looking into what I can at the moment, not organized at all.
Have you shared this on x or Reddit?
$RGDL
Interest is picking up very quietly.
That was one solid monthly update right before the much anticipated IDE decision .
These prices won’t last long imo
Great name to have on board. Thanks for sharing
Aw you so smart you timed the exit and then got back in after dust bunny came out your ass. Man I wish I could be like you with the timing!
Fisher is a true scientist and researcher. He has fully retired from his career position but can't stop working and seems to be spending his retirement working as a consultant. Just since 2023 he has been a co-author on four respected journals and penned a published opinion for Heath Physics. (Go to Google Scholar and search on 'Darrel R. Fisher'). His name has such clout that someone will likely have him peripherally involved in their research just so they can include him on as a co-author which is confirmation that someone as respected and knowledgable as him supports their work. Only the best of the best in a field get to the point that they churn out journal articles like this. Vivos having Fisher standing behind Radiogel and Isopet is a real asset.
At this year's IRPA he just presented a poster, but it does represent very recent results so it is valuable information (abstract below). As an aside he also taught a course on Sunday "Fundamental Principles of Medical Internal Radiation Dosimetry". In the description of the course they describe him as "Your instructor has more than 40 years of relevant experience in clinical radiopharmaceutical dosimetry and patient case studies, including 30 years as a member of the MIRD Committee of the Society of Nuclear Medicine and Molecular Imaging."
Abstract of poster he presented on Monday. I put in bold the items that largely put to rest my concerns in the recent X post. Dr. Fisher really doesn't care about Radiogel/Isopet what he cares about is radiation safety and clinical studies (as the google scholar search shows by how many technologies and areas he is involved). So again his stamp approval really matters as no one is going to believe he is a paid shill for a small biotech company.
Looking forward to seeing an end to the foolishness w the share price and this ridiculously low MC
yes, gonna take time, but I’ve been here 4 years and with things now coming to fruition the next 4 years of green are going to be much easier to ride
Or your triggered for selling into the last run lower than current low lol ....anyone trading around so called highs and lows currently good luck ...I've been here before in another otc and it went from 10 cents to dollars next day 🙃 enjoy the ride ...
Impatience will boomerang on this soon imo
Throw your technicals out the windows soon ...imo
I'm invested here since ADMD got out at split and back in after dust settled about 2017
Rum, I'm an investor of Vivos Inc which in someways is just a baby stock, the potential with humans is off the chart, it will take time to reach that potential. Traders are Gona trade; investors are Gona invest. The next domino is a big one! Good luck to the longs and all the investors.
Followers
|
838
|
Posters
|
|
Posts (Today)
|
12
|
Posts (Total)
|
179942
|
Created
|
09/19/06
|
Type
|
Free
|
Moderators nathanial lovethatgreen WALLnut chereb19 archilles Cameron12221 |
The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.
The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.
RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.
What are the advantages of RadioGel™?
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half-Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, Vivos’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. Vivos’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. Vivos’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. Yttrium-90 beta-emissions travel only a short distance and have a short half-life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
What is the market for RadioGel™?
Reliable sources estimate that annual sales of brachytherapy products exceed $2 billion, about half of which are in the United States. The size of the U.S. brachytherapy market for prostate cancer brachytherapy is somewhere between $90 million and $130 million per year. The market for liver and breast cancer combined is comparable.
What is Brachytherapy?
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. Vivos believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer, and 31,000 liver cancer.
Are there other markets for RadioGel™?
March 15th, 2016, Vivos Inc. announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. In August 2017 the subsidiary was changed and made into a separate operating division inside the Company.
The IsoPet™ Veterinary Solutions division will focus on bringing RadioGel™ yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers.
There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. Initial treatments are to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.
CEO and President Dr. Mike Korenko stated: “IsoPet Solutions allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that RadioGel™ is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”
Dr. Alice stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as RadioGel™ Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."
What are the steps for FDA clearance?
Vivos met at the FDA offices to discuss next steps, expectations and required testing to progress towards obtaining marketing clearance for the Y-90 RadioGel™ device. The FDA and Vivos management and consulting team are working closely in order to obtain all appropriate data and benchmarks the FDA requires in order to proceed with providing final clearance for marketing the device in the United States.
August 2016, Vivos announced a partnership with IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing. The next stage, comprised of additional in vitro and in vivo testing. Upon completion of these studies, Vivos anticipates submittal (direct De Novo) for FDA clearance for full commercialization in the U.S. (see company press releases for continual updates on this evolving process).
Press Releases 2018 ( Change in Company name and trading symbol • Jan 2, 2018)
Jan 2, 2018, Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
Press Releases 2017 ( Change in Management & Directors Dec 2016)
Dec 20, 2016, AMIC's Board of Directors Appoints Dr. Michael Korneko CEO and Dr. Carlton Cadwell Chairman of AMIC
Jan 11, 2017, AMIC's New CEO Issues Letter to Shareholders
Feb 14, 2017, AMIC's CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission
Feb 28, 2017, AMIC's New CEO Releases Shareholder Letter Announcing and Discussing their Cancer Indication Selection to pursue FDA Approval
Mar 7, 2017, AMIC's New CEO Releases Shareholder Letter Detailing Launch of Veterinary Oncology Division with Radiogel
Mar 23, 2017, Update on Feline Cancer Treatment and Improvement to Financial Structure
Jul 6, 2017, AMI Requests Pre-Submission Meeting with FDA
Jul 11, 2017, ADMD Makes Significant Improvement to its RadioGel™ Brachytherapy Product
Jul 27, 2017, ADMD to Host Shareholder Update Webcast with Live Q&A
Aug 2, 2017, Advanced Medical Isotope Corp. Announces Results of Shareholder Meeting, Welcomes Two New Members of the Board of Directors
Sep 14, 2017, Advanced Medical Isotope Corporation has its first discussions with private animal consortiums to utilize RadioGel™
Independent Analyst Research and Price Target
Presentation(s) from CEO & President, Dr. Mike Korenko.
2017 - LINK HERE
STOCK SYMBOL: OTC: RDGL
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |